Rencofilstat

Rencofilstat is Hepion Pharmaceuticals' oral cyclophilin inhibitor for MASH (metabolic dysfunction-associated steatohepatitis) with advanced fibrosis. The Phase 2 ALTITUDE-NASH study in F3 patients (severe scarring one stage before cirrhosis, n=60) completed in July 2023, and Harrison et al. reported liver function improvements measured by HepQuant DuO testing in a 2025 Liver International paper [1]. The competitive landscape has moved sharply against Hepion since: Madrigal's Rezdiffra received accelerated approval in March 2024 [4], semaglutide (Wegovy) received accelerated approval for MASH with F2/F3 fibrosis in August 2025 [6], and Hepion's confirmatory Phase 2b ASCEND-NASH trial was wound down in April 2024 [9]. The drug has FDA Fast Track (NASH) and Orphan Drug (HCC) designations [10], but the sponsor's going-concern status [11] leaves the Phase 3 path uncertain.

Novel compound, never approved for any indication. The Phase 2 ALTITUDE-NASH study in F3 MASH (NCT05461105) completed in July 2023 as an open-label, dose-ranging study across 75 mg, 150 mg, and 225 mg once-daily arms, n=60 [5]. Hepion announced the trial met its primary endpoint on liver function and multiple NASH biomarkers [12]. The pharmacokinetic and ADME supporting studies (NCT05737433, plus a food-effect study published 2023 [3]) are done, giving a reasonable PK package. Rencofilstat has FDA Fast Track designation for NASH (granted November 2021) and Orphan Drug designation for hepatocellular carcinoma (granted June 2022) [10]. No breakthrough therapy or RMAT designations. The Phase 2b ASCEND-NASH trial (NCT05513560) was intended as the confirmatory step before Phase 3, with a target of 336 subjects; enrollment was paused in April 2023 after 151 subjects, and Hepion announced wind-down in April 2024 citing resource constraints and the shifting competitive landscape [9]. No Phase 3 trial is active or announced. The 2025 Liver International publication from Harrison et al. [1] reports secondary analyses using HepQuant DuO (an updated two-sample oral-only version of the HepQuant test that produces Disease Severity Index values clinically equivalent to the original SHUNT test), rather than the biopsy-based histology endpoints the FDA requires for MASH approval. Hepion's financial position is strained: a 1-for-50 reverse stock split was effected March 17, 2025 to maintain Nasdaq listing [11], the company has disclosed going-concern language, and as of its most recent 10-K reported approximately $1.8 million in cash against roughly $3.3 million annual operating burn and an $8.3 million net loss. The drug remains alive scientifically through academic publication, but the commercial trajectory stalled after the Phase 2 F3 readout. Rencofilstat composition-of-matter patents trace to original Ciclofilin/ContraVir era filings; specific expiry and any post-grant term extension status are not disclosed in current Hepion filings and would require diligence. Expected regulatory submission timeline: none disclosed.

Cyclophilins are chaperone proteins that help other proteins fold by flipping proline-containing bonds between two shapes. Three cyclophilins matter in liver disease. CypA sits inside and outside cells and drives inflammation through the CD147 receptor [8]. CypB handles folding stress in the endoplasmic reticulum, the cell's protein factory. CypD sits in mitochondria and triggers cell death by opening the mitochondrial permeability transition pore under stress. Rencofilstat blocks all three. The anti-fibrotic logic in MASH works like this: stressed liver cells die, trigger inflammation, and activate hepatic stellate cells that lay down scar tissue. Blocking CypD reduces cell death. Blocking CypA reduces inflammatory signaling. Blocking CypB eases ER stress. The triple mechanism is appealing on paper. Validation partly borrows from cyclosporine, the original cyclophilin inhibitor, but cyclosporine's immunosuppression rules it out for chronic liver use. Rencofilstat's design win is being non-immunosuppressive, which lets you dose it long-term in a chronic disease. Animal models consistently show anti-fibrotic effects. Human validation remains thin. No cyclophilin inhibitor has ever been approved for a fibrotic indication, so Rencofilstat sits in first-in-class territory with everything that implies about biological risk.

NCT05461105 (ALTITUDE-NASH) was registered as a randomized, multi-center, open-label study in F3 MASH adults (severe/bridging fibrosis one stage before cirrhosis) with 75 mg, 150 mg, and 225 mg once-daily arms, n=60 total [5]. Primary endpoint was change from baseline in Disease Severity Index (DSI) via HepQuant SHUNT Test at Day 60 and Day 120; the 2025 Harrison et al. publication reported DSI values using the newer HepQuant DuO protocol (oral-only, two samples over 60 minutes vs. the SHUNT test's six samples over 90 minutes following IV plus oral cholate dosing) [1]. HepQuant data documents DuO and SHUNT as producing clinically equivalent DSI values, so the switch is procedural rather than a change of readout. The endpoint choice is the central concern. HepQuant measures portal-systemic shunting (blood bypassing the liver and going directly into systemic circulation, a sign of liver damage) via cholate clearance, which is a legitimate functional readout of liver physiology but not an FDA-recognized surrogate endpoint for MASH approval. The agency wants histological evidence of NASH resolution without worsening of fibrosis, or fibrosis improvement by at least one stage without worsening of NASH, from paired biopsies. The 2022 Phase 2a AMBITION trial (NCT04480710) used biomarker and liver stiffness readouts and reported directional signals [2]. Together these studies form a reasonable mechanistic case but do not clear the bar for a Phase 3 go decision without additional biopsy data. The Phase 2b ASCEND-NASH trial (NCT05513560) in F2/F3 patients was designed with more conventional endpoints but was wound down in April 2024 after enrolling 151 of 336 planned subjects [9].

Our model estimates a 5% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 23%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, weak or limited earlier-phase results, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the biggest issue. HepQuant improvements do not predict histological MASH resolution or fibrosis regression, and the FDA has shown no willingness to accept functional surrogates for Subpart H (the FDA pathway for conditional approval based on surrogate markers pending confirmatory trial results) accelerated approval in MASH outside of specific noninvasive imaging anchors. Without a biopsy-based Phase 2 win, Phase 3 is a leap. Safety risk is moderate. The non-immunosuppressive design sidesteps the main cyclosporine liability. Pan-cyclophilin inhibition over years of chronic dosing is unexplored territory. Cyclophilins participate in HIV capsid assembly and HCV replication, so chronic systemic suppression could theoretically alter host-virus interactions in co-infected patients. CypD inhibition affects mitochondrial permeability transition, which could have cardiac or renal consequences at higher exposures. Execution risk is severe. Hepion effected a 1-for-50 reverse stock split on March 17, 2025 to maintain Nasdaq compliance [11], has going-concern language in its filings, holds roughly $1.8 million in cash, and wound down its Phase 2b ASCEND-NASH confirmatory trial in April 2024 [9]. The company is not positioned to run a 1,000-plus patient Phase 3 MASH trial unaided. Commercial risk is real even in a success scenario. Rezdiffra is the first and currently only approved oral drug for MASH with F2/F3 fibrosis [4], though adoption has been constrained by its ~$47K annual list price and prior-authorization requirements. Wegovy's August 2025 approval added a second approved MASH therapy and brought GLP-1 competition into the field [6]. FGF21 agonists are advancing: pegozafermin's Phase 3 ENLIGHTEN-Fibrosis trial has a readout expected in H1 2027, and 89bio was acquired by Roche in 2025 for ~$3.5 billion, giving pegozafermin big-pharma backing [7]; efruxifermin (Akero) is in the Phase 3 SYNCHRONY program covering both pre-cirrhotic MASH and compensated cirrhosis. A late-arriving oral anti-fibrotic without clear superiority faces payer resistance, especially in a chronic silent disease where adherence to any oral therapy is modest.